Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | terminated | — | 98 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2021 |
| clinicaltrials |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | terminated | Phase 2 | 29 | BerGenBio ASAINDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT04298918 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 8, 2021 | clinicaltrials |
| NCT01934335 | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | terminated | Phase 2 | 12 | Ronald WeigelOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT03972696 | OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment(OPTIMALIIa) | terminated | N/A | 32 | Grupo de Investigación Clínica en Oncología RadioterapiaOTHER | 1 | Nov 1, 2021 | clinicaltrials |
| NCT03560102 | Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer | terminated | N/A | 1 | Kantonsspital Winterthur KSWOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT02426489 | Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System(MRI-PEM) | terminated | N/A | 1 | Weinberg Medical Physics LLCINDUSTRY | 0 | Oct 7, 2021 | clinicaltrials |
| NCT01957514 | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy(ITOMIC) | terminated | — | 31 | University of WashingtonOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00110136 | St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer | terminated | Phase 2 | 9 | Wake Forest University Health SciencesOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02404506 | Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer | terminated | Phase 2 | 78 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02833766 | Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer | terminated | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02907918 | Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer(PALTAN) | terminated | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | terminated | Phase 2 | 16 | PfizerINDUSTRY | 7 | Sep 27, 2021 | clinicaltrials |
| NCT03894007 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer(PREDIXIIHER2) | terminated | Phase 2 | 6 | Renske AltenaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT03822715 | NEOBREADS: Neoadjuvant Breast Diet Study(NEOBREADS) | terminated | Phase 1 | 2 | Monica MitaOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03795012 | Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | terminated | Phase 2 | 22 | MedSIROTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT04031885 | A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | terminated | Phase 4 | 4 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 24, 2021 | clinicaltrials |
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT01988090 | High Dose Vitamin D vs Standard Dose Vitamin D Study | terminated | Phase 2 | 93 | Mothaffar RimawiOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03326674 | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC(CONTESSA) | terminated | Phase 3 | 685 | Odonate Therapeutics, Inc.INDUSTRY | 19 | Jul 30, 2021 | clinicaltrials |
| NCT03858972 | Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC(CONTESSA 2) | terminated | Phase 2 | 152 | Odonate Therapeutics, Inc.INDUSTRY | 6 | Jul 30, 2021 | clinicaltrials |
| NCT03952325 | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC(CONTESSA TRIO) | terminated | Phase 2 | 294 | Odonate Therapeutics, Inc.INDUSTRY | 3 | Jul 30, 2021 | clinicaltrials |
| NCT03723863 | Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy | terminated | N/A | 15 | University of WashingtonOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT02149173 | F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy | terminated | N/A | 29 | University of WashingtonOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT01755130 | Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer | terminated | N/A | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT03982004 | Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer | terminated | Phase 1 | 1 | Washington University School of MedicineOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT03905343 | Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC | terminated | Phase 3 | 25 | Swiss Cancer InstituteOTHER | 3 | Jun 16, 2021 | clinicaltrials |
| NCT00542191 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | terminated | Phase 2 | 30 | Leo W. Jenkins Cancer CenterOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03983395 | Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Ichnos Sciences SAINDUSTRY | 1 | May 24, 2021 | clinicaltrials |
| NCT02936206 | Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | terminated | Phase 1 | 2 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT01861054 | Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer | terminated | Phase 2 | 20 | Dompé Farmaceutici S.p.AINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT03143894 | Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation | terminated | N/A | 7 | Johns Hopkins UniversityOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03051672 | Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02569801 | A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy(HydranGea) | terminated | Phase 2 | 71 | Genentech, Inc.INDUSTRY | 6 | Apr 23, 2021 | clinicaltrials |
| NCT02454777 | High-Intensity Interval Training for Stage I-III Breast Cancer Patients | terminated | N/A | 31 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT00461773 | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer | terminated | Phase 2 | 5 | Yale UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT04084600 | Effects of Manual Therapy on Chronic Pain and Functionality of Breast Cancer Survivors | terminated | N/A | 10 | University of the State of Santa CatarinaOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT00296010 | Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer(CASA) | terminated | Phase 3 | 77 | ETOP IBCSG Partners FoundationNETWORK | 9 | Feb 23, 2021 | clinicaltrials |
| NCT00003654 | Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer | terminated | N/A | 200 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00470249 | Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer | terminated | Phase 2 | 5 | University of SouthamptonOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02730091 | A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease(VICTORIANE) | terminated | Phase 3 | 98 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 16, 2021source: clinicaltrials